Koshine 826 (Pyrilutamide) For Hair Loss - Is It Effective?
Hair loss is a significant concern for millions of people worldwide, especially as they age. For many individuals, especially those with androgenetic alopecia (AGA), commonly known as male or female pattern baldness, hair thinning can be distressing. While there are various treatments available, the introduction of Koshine 826 (formerly known as pyrilutamide) as a new cosmetic solution marks a potentially exciting development in the treatment of hair loss, reducing the need for hair transplants.
Developed as an anti-androgenic topical, Koshine 826 works by targeting the root cause of androgenic hair loss. This article explores the science behind Koshine 826, its clinical studies, safety profile, how it compares to other treatments, and its potential future in the cosmetic and pharmaceutical markets.
What is Koshine 826?
Koshine 826 is a topical anti-androgen treatment developed to address hair loss caused by androgenic alopecia (AGA). Originally known as Pyrilutamide or KX-826, Koshine 826 works by blocking the androgen receptors in hair follicles, preventing the negative effects of dihydrotestosterone (DHT) on hair growth.
Androgens, such as testosterone and DHT, play a pivotal role in the development of AGA. DHT, in particular, binds to androgen receptors in hair follicles, leading to their miniaturization and eventually causing hair to become thinner and weaker. This process results in the characteristic thinning and shedding of hair seen in both men and women with pattern baldness.
What sets Koshine 826 apart from other hair loss treatments is its mechanism of action. Unlike finasteride or dutasteride, which inhibit the enzyme 5-alpha-reductase (responsible for converting testosterone into DHT), Koshine 826 works by blocking the androgen receptor itself, preventing DHT from attaching to the follicle. This targeted approach offers the potential for a more direct effect on hair follicles without affecting other systems in the body, thus reducing the risk of systemic side effects.
Initially developed for the treatment of both androgenic alopecia and acne vulgaris, Koshine 826 has undergone extensive clinical trials and is now marketed as a cosmetic product to treat hair loss. Its launch as a cosmetic treatment marks an important shift in how the product can be made available to the public.
The Mechanism of Action of Koshine 826
Koshine 826 operates by targeting the androgen receptor in the scalp's hair follicles. This receptor is responsible for mediating the effects of androgens such as DHT, which are implicated in the miniaturization of hair follicles in individuals with androgenetic alopecia. By binding directly to the androgen receptor, Koshine 826 prevents DHT and testosterone from binding to these receptors, thereby halting or slowing the process of follicle miniaturization.
While DHT is known to shrink hair follicles, reducing their size and lifespan, Koshine 826 offers a different approach compared to other treatments. Rather than focusing on reducing DHT levels systemically (as finasteride does), Koshine 826 focuses specifically on blocking the receptor that DHT binds to. This targeted method could potentially provide a more effective and localized treatment for hair loss, without affecting the rest of the body.
In essence, Koshine 826 is designed to prevent the harmful effects of DHT on hair follicles, thereby encouraging healthier hair growth. This receptor-blocking method is thought to be a safer alternative to systemic anti-androgens, as it avoids the broader hormonal changes that might lead to undesirable side effects.
Koshine 826 Clinical Trials: Does It work for hair loss?
Like any new treatment, Koshine 826 has undergone a series of clinical trials to evaluate its efficacy and safety. These trials have focused on its ability to stimulate hair regrowth in individuals with androgenic alopecia. While some trials have shown positive results, others have yielded more cautious findings.
Study 1: Female Pattern Hair Loss
One of the first trials conducted on Koshine 826 involved 160 women with female-pattern hair loss. This 24-week, randomized, double-blind, placebo-controlled study was conducted in China and tested various concentrations of Koshine 826 (0.25% and 0.5%) applied once or twice daily. The primary outcome of the trial was the change in hair growth, measured by the number of terminal hairs (thick, pigmented hairs) in the target area.
The results of this trial indicated that the 0.5% once-daily dose was the most effective, showing an increase of 11.39 hairs per cm² compared to the placebo. The researchers noted that participants began seeing improvements as early as week 12. Importantly, Koshine 826 was well tolerated, with no significant side effects reported, although the specifics of any mild adverse effects were not fully disclosed.
Study 2: Male Pattern Hair Loss
A similar study was conducted on 120 men with male-pattern hair loss. In this 24-week trial, participants were treated with various concentrations of Koshine 826, including 0.25% twice daily, 0.5% once daily, 0.5% twice daily, or a placebo. The best results were seen with the 0.5% twice-daily application, which resulted in an increase of 15.34 hairs per cm² from baseline compared to the placebo. This increase was statistically significant, but no details were provided on the variability or statistical analysis of the results.
Although the treatment showed promise, the trial results were not as definitive as many had hoped, especially considering the variability in results and the lack of statistically significant differences between the active treatment and placebo in some instances. However, the safety profile remained positive, with mild side effects, such as pruritus (itchy skin) and contact dermatitis, reported in a small percentage of participants.
Study 3: Safety and Pharmacokinetics
A Phase I trial in the United States assessed the safety, tolerability, and pharmacokinetics of Koshine 826 in 40 healthy men with male-pattern hair loss. The study used ascending doses of Koshine 826 (ranging from 0.3% to 9.6%) and measured the concentration of the drug in the blood. The results showed that the drug was well tolerated, with mild contact dermatitis being the only adverse event. The concentrations of Koshine 826 in the blood were low, indicating that the drug’s systemic effects were minimal.
This phase I trial confirmed that Koshine 826 is a safe topical treatment with low systemic absorption, which is one of the reasons it is seen as a promising alternative to oral anti-androgen treatments like finasteride, which can have more extensive systemic effects.
Study 4: Efficacy and Safety in the US
A Phase II trial in the US involved 123 men with male-pattern hair loss. Participants were treated with 0.25% once-daily, 0.5% once-daily, or 0.5% twice-daily Koshine 826. After 24 weeks, the study found that the twice-daily 0.5% treatment resulted in a modest increase of 10 hairs per cm² compared to baseline. While this result was statistically significant, it did not show a dramatic improvement compared to the placebo group, raising concerns about the clinical impact of the treatment.
Phase III Trials and Marketing Shift
Despite the mixed results from these clinical trials, Kintor Pharmaceuticals continued to move forward with the commercialization of Koshine 826. In 2024, the company launched Koshine 826 Anti Hair Loss Solution as a cosmetic product. This shift allowed the product to be sold without the need for FDA approval, as cosmetics do not require evidence of efficacy in the same way pharmaceutical drugs do.
While the clinical trials have not demonstrated groundbreaking results, the availability of Koshine 826 as a cosmetic product provides individuals with an option for treating hair loss, even if the long-term efficacy remains uncertain. The product is currently available for purchase online, where it is marketed as a solution that can reduce hair loss and promote visible hair growth within weeks of use.
Is Koshine 826 Safe?
Based on the available data, Koshine 826 appears to be a well-tolerated topical treatment. The most common side effects reported in clinical trials were mild and included pruritus (itchiness) and contact dermatitis. There were no severe adverse events or systemic effects reported, which is one of the key benefits of using a topical treatment rather than an oral anti-androgen.
Despite these positive findings, it’s important to note that the safety data is still limited, and no long-term studies have been conducted to evaluate the drug’s effects over time. As with any new treatment, it is essential for users to monitor their responses and consult with a healthcare provider if they experience any discomfort or unusual side effects.
Koshine 826 as a Cosmetic: The Legal and Marketing Implications
One of the most significant developments in the journey of Koshine 826 is its rebranding as a cosmetic product. Kintor Pharmaceuticals’ decision to sell Koshine 826 as a cosmetic rather than a drug was strategic, allowing them to bypass the more stringent regulatory requirements for drug approval. Cosmetics, unlike pharmaceuticals, do not need to prove their efficacy before being sold to the public, as they are not intended to treat or cure diseases.
This shift in marketing strategy has allowed Koshine 826 to enter the market more quickly, but it also means that the product is not subject to the same level of scrutiny as other hair loss treatments like Minoxidil. Consumers are advised to approach the product with caution, as there is still limited published data supporting its efficacy.
What the Future Holds for Koshine 826
Looking ahead, the future of Koshine 826 is promising, although it remains uncertain. The ongoing Phase II/III trial testing a 1% concentration of Koshine 826 could provide more conclusive evidence of its efficacy. If the 1% solution proves to be significantly more effective than the 0.5% formulation, it could become a major player in the treatment of androgenetic alopecia.
However, it’s important to note that Koshine 826 is not the only treatment option available. Other treatments, such as minoxidil and finasteride, continue to be widely used, and future clinical trials will need to compare Koshine 826 directly against these established treatments to determine its place in the market.
Conclusion
Koshine 826 is a promising new option for individuals experiencing hair loss, particularly those suffering from androgenetic alopecia. Its novel mechanism of action—blocking the androgen receptor to prevent the harmful effects of DHT—sets it apart from traditional treatments. Although clinical trials have shown mixed results, Koshine 826’s availability as a cosmetic treatment allows it to reach consumers who may benefit from this non-invasive approach.
While further studies are needed to fully establish the efficacy and safety of Koshine 826, its entry into the market provides hope for those looking for new solutions to hair loss. As research continues, Koshine 826 may become an important tool in the battle against hair thinning, offering a promising alternative for those seeking to restore their hair and confidence. If you are struggling with hair loss, a consultation with one of our trichology team can assess the cause, and we can put together a tailored package of treatment options, with hair transplant costs becoming more affordable, the surgery is an easy way to restore your looks and is now within reach for many people.
Get back to Great Hair
in 3 Easy Steps:
01
Arrange Free Consultation
Speak to one of our specialist consultants for expert advice on our range of different hair loss treatments
02
Book Your Procedure
Place a deposit to reserve a time slot at one of the My Hair UK clinics across the UK
03
Attend Your Surgery
Arrive on the day and our specialist surgical team will look after your every need
